ReviewRecent advances in drug delivery and formulation2026
Advancement in Nanotablet Research: An Overview.
Review in Recent advances in drug delivery and formulation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Modern technologies such as nanotechnology are being applied in almost every sector to deliver affordable, environmentally friendly products. The integration of nanotechnology in medicine has revolutionized drug delivery systems, with nanotechnology emerging as a promising frontier. This review explores the synthesis and characterization of nanotablet drug formulations designed to enhance their potential across various applications. By employing characterization techniques such as X-ray diffraction, electron microscopy, and physisorption analysis, researchers have developed innovative drug delivery systems like Sophora Alopecuroides nanotablets to treat deadly diseases such as cancer. Evaluation of pre- and post-compression results indicated that nanotablets exhibited good hardness and flow properties, making these formulations potential drug delivery systems for enhanced bioavailability and sustained release properties. Specifically, sublingual sufentanil nanotablets, such as Zalviso®, have demonstrated efficacy in managing moderate to severe pain in healthcare settings when used in conjunction with a PCA device. However, recent regulatory updates indicate changes in the marketing authorization status of Zalviso®. In conclusion, this novel approach for synthesizing nanotablets presents a promising avenue for diverse applications, and based on the results, it is worth considering for future work.
Indexed as
Identifiers
40370229What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.